newsfilter
← Latest News
Business Wire·

AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Following positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Patient dosing completed in